The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH. Based on data from the Beamion LUNG-1 ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

The U.S. Food and Drug ​Administration on Friday approved Bristol ‌Myers Squibb's combination treatment for adults and ...

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients ...

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.

The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies considerably by race, even though 3 decades have passed since researchers first ...

On Wednesday, March 25, Columbus resident and lung cancer survivor, Nancy Vandespool, will meet with her members of Congress for the American Lung Association’s 11th annual LUNG FORCE Advocacy Day in ...

When Dan Hannon, 72, received guidance to have part of a lung taken out whether nodules were cancerous or not, he wanted a second opinion to see if he would indeed live the rest of his life without a ...